Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model


When given orally to a transgenic mouse model of Alzheimer disease, cyclohexanehexol stereoisomers inhibit aggregation of amyloid β peptide (Aβ) into high-molecular-weight oligomers in the brain and ameliorate several Alzheimer disease–like phenotypes in these mice, including impaired cognition, altered synaptic physiology, cerebral Aβ pathology and accelerated mortality. These therapeutic effects, which occur regardless of whether the compounds are given before or well after the onset of the Alzheimer disease–like phenotype, support the idea that the accumulation of Aβ oligomers has a central role in the pathogenesis of Alzheimer disease.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Cyclohexanehexols improve behavior in TgCRND8 mice.
Figure 2: Cyclohexanehexols improve pathological characteristics in TgCRND8 mice.
Figure 3: Spatial reference memory test was performed in 6-month-old mice after 28 d of treatment, beginning at 5 months of age (n = 10 mice per treatment arm).
Figure 4: Dot-blot analyses of soluble oligomeric Aβ in TgCRND8 left untreated or treated with epi-cyclohexanehexol (a) or scyllo-cyclohexanehexol (b).
Figure 5: Dose-dependent effects of scyllo-cyclohexanehexol on 4-month-old TgCRND8 mice.


  1. 1.

    NOTE: In the version of this article initially published online, there was an error in Table 1. In the 6-month prophylactic study under Scyllo-cyclohexanehexol, the soluble Aβ40 level should be 105 ± 8 instead of 1,105 ± 8. The error has been corrected for the HTML and print versions of the article.


  1. 1

    Selkoe, D.J. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J. Clin. Invest. 110, 1375–1381 (2002).

    CAS  Article  Google Scholar 

  2. 2

    Glabe, C.C. Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Aβ. Subcell. Biochem. 38, 167–177 (2005).

    CAS  Article  Google Scholar 

  3. 3

    McLaurin, J. & Chakrabartty, A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J. Biol. Chem. 271, 26482–26489 (1996).

    CAS  Article  Google Scholar 

  4. 4

    McLaurin, J. & Chakrabartty, A. Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid membranes. Eur. J. Biochem. 245, 355–363 (1997).

    CAS  Article  Google Scholar 

  5. 5

    Koppaka, V. & Axelson, P.H. Accelerated accumulation of amyloid beta proteins on oxidatively damaged lipid membranes. Biochemistry 39, 10011–10016 (2000).

    CAS  Article  Google Scholar 

  6. 6

    Mizuno, T. et al. Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J. Biol. Chem. 274, 15110–15114 (1999).

    CAS  Article  Google Scholar 

  7. 7

    Choo-Smith, L.P. & Surewicz, W.K. The interaction between Alzheimer amyloid beta(1–40) peptide and ganglioside GM1-containing membranes. FEBS Lett. 402, 95–98 (1997).

    CAS  Article  Google Scholar 

  8. 8

    Yanagisawa, K. et al. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1, 1062–1066 (1995).

    CAS  Article  Google Scholar 

  9. 9

    Auton, M. & Bolen, D.W. Predicting the energetics of osmolyte-induced protein folding/unfolding. Proc. Natl. Acad. Sci. USA 102, 15065–15068 (2005).

    CAS  Article  Google Scholar 

  10. 10

    McLaurin, J., Franklin, T., Chakrabartty, A. & Fraser, P.E. Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. J. Mol. Biol. 278, 183–194 (1998).

    CAS  Article  Google Scholar 

  11. 11

    McLaurin, J., Goloumb, R., Jurewicz, A., Antel, J.P. & Fraser, P.E. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit Aβ-induced toxicity. J. Biol. Chem. 275, 18495–18502 (2000).

    CAS  Article  Google Scholar 

  12. 12

    Chishti, M.A. et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 21562–21570 (2001).

    CAS  Article  Google Scholar 

  13. 13

    Janus, C. et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979–982 (2000).

    CAS  Article  Google Scholar 

  14. 14

    Morris, R. Development of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47–60 (1984).

    CAS  Article  Google Scholar 

  15. 15

    Klein, W.L. Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as a new vaccine and drug targets. Neurochem. Int. 41, 345–352 (2002).

    CAS  Article  Google Scholar 

  16. 16

    Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486–489 (2003).

    CAS  Article  Google Scholar 

  17. 17

    Spector, R. Myo-inositol transport through the blood-brain barrier. Neurochem. Res. 13, 785–787 (1988).

    CAS  Article  Google Scholar 

  18. 18

    Uldry, M. et al. Identification of a mammalian H(+)-myo-inositol symporter expressed predominantly in the brain. EMBO J. 20, 4467–4477 (2001).

    CAS  Article  Google Scholar 

  19. 19

    Uldry, M. & Thorens, B. The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch. 447, 480–489 (2004).

    CAS  Article  Google Scholar 

  20. 20

    Shetty, H.U. & Hollway, H.W. Assay of myo-inositol in cerebrospinal fluid and plasma by chemical ionization mass spectrometry of the hexaacetate derivative. Biol. Mass Spectrom. 23, 440–444 (1994).

    CAS  Article  Google Scholar 

  21. 21

    McLaurin, J. et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8, 1263–1269 (2002).

    CAS  Article  Google Scholar 

  22. 22

    Frenkel, D., Katz, O. & Solomon, B. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. USA 97, 11455–11459 (2000).

    CAS  Article  Google Scholar 

  23. 23

    Bard, F. et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against disease-like neuropathology. Proc. Natl. Acad. Sci. USA 100, 2023–2028 (2003).

    CAS  Article  Google Scholar 

  24. 24

    Nicoll, J.A. et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9, 448–452 (2003).

    CAS  Article  Google Scholar 

  25. 25

    Hock, C. et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547–554 (2003).

    CAS  Article  Google Scholar 

  26. 26

    Tanaka, M. et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10, 148–154 (2004).

    CAS  Article  Google Scholar 

  27. 27

    Lesne, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352–357 (2006).

    CAS  Article  Google Scholar 

  28. 28

    Fisher, S.K.,, Novak, J.E., & Agranoff, B.W. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J. Neurochem. 82, 736–754 (2002).

    CAS  Article  Google Scholar 

  29. 29

    Vaucher, E. et al. Object recognition memory and cholinergic parameters in mice expressing human presenilin 1 transgenes. Exp. Neurol. 175, 398–406 (2002).

    CAS  Article  Google Scholar 

  30. 30

    Mount, H.T. et al. Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia. J. Neurochem. 88, 1449–1454 (2004).

    CAS  Article  Google Scholar 

  31. 31

    Wiltfang, J. et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 81, 481–496 (2002).

    CAS  Article  Google Scholar 

  32. 32

    Haccou, P. & Mellis, E. Statistical Analysis of Behavioural Data 120–186 (Oxford Univ Press, Oxford, 1995).

    Google Scholar 

  33. 33

    Chen, F. et al. Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells. J. Biol. Chem. 275, 36794–36802 (2000).

    CAS  Article  Google Scholar 

  34. 34

    Phinney, A. et al. No hippocampal neuron or synaptic bouton loss in learning-impaired aged β-amyloid precursor protein-null mice. Neuroscience 90, 1207–1216 (1999).

    CAS  Article  Google Scholar 

  35. 35

    Hu, L. et al. The impact of Aβ-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in Alzheimer's disease-like transgenic mice. Neuroscience 121, 421–432 (2003).

    CAS  Article  Google Scholar 

Download references


The authors thank C. Glabe for the oligomeric specific antibody, P. Mathews for the C1/6.1 antibody and R. Ahrens and P. Horne for technical assistance. The authors acknowledge support from the Ontario Alzheimer's Society (to H.T.J.M., P.H., P.E.F., D.W., J.M.), Canadian Institutes of Health Research (to H.T.J.M., P.H., P.E.F., D.W., J.M.), the Natural Sciences and Engineering Research Council of Canada (to J.M.), Canadian Foundation for Innovation (to H.T.J.M., P.H., P.E.F., D.W., J.M.), Ontario Research and Development Challenge Fund (to J.M., P.H., D.W., P.E.F.) Howard Hughes Medical Institute (to P.H.) and the Scottish Rite and Cryptic Foundations (to J.M.).

Author information




J.M., A.L.P., H.T.J.M. and P.S.G.-H. designed research. M.E.K., M.E.B., C.A.H., M.H.L.L., A.A.D., J.E.C., J.E.F., M.F.L., F.C. and S.S.N.W. performed research. J.M., M.E.K., C.A.H., A.L.P. and H.T.J.M. analyzed the data. J.M., H.T.J.M., P.E.F., D.W. and P.S.G.-H. wrote the manuscript.

Corresponding author

Correspondence to JoAnne McLaurin.

Ethics declarations

Competing interests

JoAnne McLaurin, Paul E. Fraser, David Westaway and Peter St. George-Hyslop and the University of Toronto have licensed this technology to a private-sector company from which support for a research program is derived.

JoAnne McLaurin is named as inventor on patent applications relating to this technology.

Supplementary information

Supplementary Fig. 1

Cyclohexanehexol stereoisomer structures. (PDF 16 kb)

Supplementary Fig. 2

Spatial reference memory version of the Morris water maze test in 6-month-old TgCRND8 mice untreated and treated with mannitol. (PDF 98 kb)

Supplementary Fig. 3

At 6 months of age, the plaque burden and astrogliosis in TgCRND8 mice untreated, epi- and scyllo-cyclohexanehexoltreated mice were examined. (PDF 240 kb)

Supplementary Fig. 4

A cue test was performed at the end of the spatial memory version of the Morris water maze test. (PDF 25 kb)

Supplementary Fig. 5

In vitro γ-secretase assay in HEK293 cells trasfected with human PPswe. (PDF 143 kb)

Supplementary Table 1

Overall effect of cyclohexanehexols on cognitive function. (PDF 26 kb)

Supplementary Methods (PDF 31 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

McLaurin, J., Kierstead, M., Brown, M. et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12, 801–808 (2006).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing